Cerevel Therapeutics
NEWS
Cerevel is now part of AbbVie.
The deal, announced late Wednesday, will provide AbbVie with access to Cerevel Therapeutics’ pipeline of clinical-stage and preclinical candidates for psychiatric and neurological diseases.
With a potential $509 billion up for grabs by 2028, companies including Biogen, Sage, Karuna Therapeutics and Cerevel Therapeutics are vying to bring their drugs across the regulatory finish line.
Life sciences news sometimes flies under the radar. So here’s a look at a few stories you may have missed.
Two years ago, Cerevel Therapeutics spun out of Pfizer. It then took an unusual approach, merging with a special purpose acquisition company, Arya Sciences Acquisition Corp II. Arya was designed specifically to acquire or merge with another company.
Cerevel Therapeutics, which spun out of Pfizer two years ago, entered into a business combination deal with Arya Sciences Acquisition Corp II, a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s appointments.
JOBS
IN THE PRESS